NVS - Calithera Looks To Combination Therapies To Tackle Cancer
Calithera Biosciences (CALA) is a good speculative biotech to take a look at. It is using its clinical product CB-839 in combination with already approved therapies to tackle renal cell carcinoma. This approach could be worthwhile, especially since this biotech has two shots on goal to tackle this cancer. If it all plays out well, CB-839 could potentially be combined with a host of other drugs to target a variety of tumors.
CB-839 Plus Chemotherapy
CB-839 plus everolimus is being explored in a Phase 2 renal cell carcinoma study. Everolimus (AFINITOR) is a